Dermatology is one of the most active therapeutic areas in drug development today. Conditions such as atopic dermatitis, psoriasis, hidradenitis suppurativa, and alopecia areata have become focal points for a new generation of biologics, small molecules, and emerging cell and gene therapies. Yet despite the pipeline activity, early-phase development in dermatology comes with its own set of challenges — particularly around immune endpoint selection, biomarker strategy, and the complexity of demonstrating early proof-of-concept in a visible but mechanistically intricate disease area.
At hVIVO, the clinical infrastructure, laboratory capabilities, and drug development expertise we have built across immunology, clinical pharmacology, and early-phase oncology and autoimmune programmes are directly applicable to sponsors developing treatments for skin conditions. This article explores why, and what that means in practice.
Dermatology Is an Immunology Problem First
The most significant shift in dermatology drug development over the past two decades is the recognition that many common skin conditions are fundamentally immune-mediated. Atopic dermatitis involves dysregulation of the Th2 axis. Psoriasis is driven by the IL-17 and IL-23 pathways. Even conditions once considered primarily structural — such as some forms of scarring — are being reframed around inflammatory signalling.
This means that sponsors developing dermatology assets need laboratory infrastructure capable of characterising immune responses with precision — including cytokine profiling, T-cell phenotyping, and cellular immune assays. hVIVO's immunology laboratory operates ELISpot, intracellular cytokine staining, and flow cytometry platforms, all of which are directly relevant to characterising immune modulation in early-phase dermatology studies.
Critically, these capabilities are not siloed. At hVIVO, laboratory services are integrated with clinical delivery, meaning biomarker data generated during a Phase I study can be interpreted in real time alongside clinical pharmacology endpoints. For dermatology sponsors seeking to build a pharmacodynamic story early — to demonstrate that a candidate is hitting its target and modulating the right immune pathways before entering larger efficacy studies — this integrated model is a meaningful advantage.
Early-Phase Clinical Pharmacology in Dermatology
Many dermatology programmes involve systemically administered agents — including JAK inhibitors, IL-receptor antagonists, and bispecific antibodies — where the same clinical pharmacology questions apply as in any other immune-mediated indication: How is the drug absorbed and distributed? What are the PK/PD relationships? Are there drug-drug interaction risks given the likelihood of polypharmacy in patients with moderate-to-severe disease?
hVIVO's clinical pharmacology teams, operating from Phase I units in London and Kiel, are experienced in designing and executing first-in-human and early-phase studies for immunology-adjacent assets. Capabilities include PK/PD modelling and simulation, bioequivalence and food-effect studies, and drug-drug interaction designs — all supported by on-site analytical laboratories to minimise sample transit and data latency.
For topical agents, where local bioavailability and systemic exposure are both of interest, our clinical pharmacology and bioanalytical teams can design studies with appropriate sampling strategies to characterise both compartments — an important consideration as dermatology moves toward combination approaches and dual-modality therapies.
Biomarker Strategy: The Difference Between an Early Win and a Late Failure
One of the most common failure modes in dermatology drug development is entering Phase II without a credible pharmacodynamic hypothesis. A sponsor may have strong preclinical data showing target engagement, but if the Phase I design doesn't include the right immune or biomarker endpoints, the programme moves forward on faith rather than evidence.
hVIVO's assay development and validation team works with sponsors from the earliest stages to design fit-for-purpose assays for clinical programmes. For dermatology candidates, this could include cytokine panels, PBMC-based functional assays, or flow cytometry panels to track immune cell subsets in peripheral blood as a surrogate for tissue-level changes.
Our PBMC processing and isolation capability — conducted to GCP-grade standards — ensures that cellular material collected during Phase I visits is handled with the fidelity required to generate interpretable immune data. For dermatology programmes where mechanistic understanding of a drug's mode of action is central to the regulatory and commercial story, this translational capability is not ancillary; it is core.
The Value of Integrated Consultancy for Dermatology Sponsors
Dermatology drug development also presents specific regulatory and strategic challenges. Endpoint selection for early studies, the right patient population for proof-of-concept, the use of validated clinical scores (such as EASI, IGA, or PASI) as primary versus secondary endpoints in Phase II — these are decisions that benefit from experienced regulatory and clinical pharmacology input well before the first site is activated.
hVIVO's drug development consulting team brings together expertise across regulatory strategy, statistics and study design, PK/PD modelling, and non-clinical development. For dermatology sponsors — particularly biotech companies and startups entering clinical development for the first time — access to integrated strategic advice alongside operational delivery is a material accelerator. It removes the friction of coordinating multiple specialist advisors and creates a coherent development strategy rather than a patchwork of individual outputs.
Our due diligence and investor readiness consulting is also increasingly relevant for dermatology companies, where the pipeline is competitive and investors expect sponsors to articulate not just the asset opportunity, but the evidence-generation strategy — what data will be generated by what stage, and how that data maps to a regulatory and partnering pathway.
Looking Ahead
The dermatology pipeline continues to evolve rapidly. Emerging areas — including the microbiome's role in skin barrier function, the intersection of dermatology and metabolic disease, and the expansion of cell and gene therapy into genodermatoses — will require increasingly sophisticated clinical and laboratory infrastructure to generate credible early data.
hVIVO is committed to expanding the breadth of therapeutic areas where our integrated early-phase capabilities can support sponsors. For dermatology companies at the preclinical-to-clinical transition, or those looking to strengthen the pharmacodynamic and biomarker story within existing programmes, we welcome the conversation.
Interested in discussing your dermatology programme? Contact our team to explore how hVIVO's integrated clinical, laboratory, and consultancy capabilities can support your development goals.
hVIVO is an integrated early-phase clinical development organisation. Our capabilities span Phase I–III clinical delivery, laboratory services, human challenge models, drug development consultancy, and biobank solutions. We work with pharma, biotech, CROs, and startups across a range of therapeutic areas.
